RESERPINE
LOE ApproachingNDAORALTABLET
Approved
Mar 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 10h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Reserpine is an oral tablet small molecule approved in 1955 for hypertension and other cardiovascular indications. It is an alkaloid derivative that acts as a monoamine depleter, reducing sympathetic nervous system activity. This legacy antihypertensive agent has largely been superseded by newer drug classes but maintains a niche market.
LOE Approaching
Declining
Minimal commercial team expansion expected; role focus is on cost management and patient retention rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on reserpine offers limited career growth within a legacy product approaching end-of-life. Roles emphasize cost containment, regulatory maintenance, and managed decline rather than innovation or market expansion.
Product Manager (Legacy)Medical Science Liaison
Worked on RESERPINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.